The health secretary has chipped away at the idea that immunizing children against measles and other diseases is a public ...

Shares of Novavax Inc. NVAX shed 3.23% to $6.00 Thursday, on what proved to be an all-around dismal trading session for the ...

The former top vaccines official at the Food and Drug Administration criticized Health and Human Services Secretary Robert F.

Directives from President Donald Trump's administration to freeze grant funding from the National Institutes of Health may ...

(Reuters) -Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and Human Services ...

As in previous studies, the SHIELD study found health care workers who received the Novavax vaccine reported significantly ...

Novavax shifts to a partnership-focused strategy with a $500M Sanofi deal. Despite regulatory and competitive risks. See why ...

Novavax (NasdaqGS:NVAX) recently announced promising preliminary results from the SHIELD-Utah study, which highlighted fewer and less severe reactogenicity symptoms for its COVID-19 Vaccine, ...

Dr. Peter Marks, an ex-FDA vaccine official, is warning of a fundamental change at the agency—where vaccine skepticism now ...

Novavax (NVAX) closed the most recent trading day at $6.39, moving -0.31% from the previous trading session. This move lagged the S&P 500's daily loss of 0.17%. Meanwhile, the Dow experienced a drop ...

According to TipRanks, Stranahan is an analyst with an average return of -15.0% and a 32.39% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Candel Therapeutics, ...